A Systematic Literature Review on the Cost-Effectiveness of Apixaban for Stroke Prevention in Non-valvular Atrial Fibrillation

被引：19

作者：

Pinyol C. ^{[1
]}

Cepeda J.M.ª ^{[2
]}

Roldan I. ^{[3
]}

Roldan V. ^{[4
]}

Jimenez S. ^{[5
]}

Gonzalez P. ^{[5
]}

Soto J. ^{[6
]}

机构：

[1] INNOVA Strategic Consulting, Barcelona

[2] Internal Medicine Department, Hospital Comarcal Vega Baja, Orihuela, Alicante

[3] Cardiology Department, Hospital La Paz, Madrid

[4] Hematology Department, Hospital Morales Meseguer, Murcia

[5] Health Economics and Outcomes Research, Bristol-Myers Squibb, Madrid

[6] Health Economics and Outcomes Research, Pfizer S.L.U., Madrid

来源：

Cardiology and Therapy | 2016年 / 5卷 / 2期

关键词：

Apixaban; Economic evaluation; Non-valvular atrial fibrillation; Systematic literature review;

D O I：

10.1007/s40119-016-0066-2

中图分类号：

学科分类号：

摘要：

Introduction: Economic evaluations are becoming increasingly important due to limitations in economic resources, the expense of many new treatments, the need to allocate health spending as effectively as possible, and the need to inform decision makers. Based on the data from the apixaban studies (ARISTOTLE and AVERROES), several economic evaluations have been performed in various countries to demonstrate the efficacy of apixaban versus warfarin and aspirin or other new oral anticoagulants (NOACs) for preventing stroke in patients with non-valvular atrial fibrillation (NVAF).The aim of this study was to perform a systematic literature review of published economic evaluations with apixaban in the indication of stroke prevention in patients with NVAF. Methods: A search in PubMed, Cochrane Library, Google Scholar, and Index Medicus Español was conducted in June 2015. Inclusion and exclusion criteria were established. The main characteristics were recorded for all relevant articles after being reviewed. In addition, a weighted version of the Drummond’s checklist was used to further assess the quality of the selected studies. Results: After review, 26 cost-effectiveness analyses through Markov models were included; the identified economic evaluations represent different willingness-to-pay (WTP) thresholds, discount rates, medical costs, and healthcare systems. Apixaban was compared with warfarin/acenocoumarol in 7 of them (27%), with warfarin/NOACs in 14 (54%), with aspirin in 2 (8%), and with warfarin/aspirin in 3 (11%). Models were conducted from Europe (69%), USA (23%), Australia (4%), and Latin America (4%). All models reported cost/quality-adjusted life years (QALYs) gained, 92% reported using a payer perspective, and 8% using a societal perspective; the median quality score of the selected studies was 89 (out of 119), with a range of 55–103. In models performed in Europe, incremental cost-effectiveness ratios (ICERs) of apixaban versus warfarin ranged from €5607/QALY to €57,245/QALY, while ICERs versus aspirin ranged from being dominant to €7334/QALY. In models carried out in the USA, ICERs of apixaban versus warfarin ranged from being dominant to $93,063/QALY. Conclusion: Different cost-effectiveness analyses suggest that apixaban is a cost-effective therapeutic option according to the WTP thresholds used in countries where cost-effectiveness analyses, were performed. Funding: BMS and Pfizer. © 2016, The Author(s).

引用

页码：171 / 186

页数：15

共 42 条

[1] Granger C.B., Alexander J.H., McMurray J.J.V., Et al., Apixaban versus warfarin in patients with atrial fibrillation, N Engl J Med, 365, pp. 981-992, (2011)
[2] Connolly S.J., Eikelboom J., Joyner C., Et al., Apixaban in patients with atrial fibrillation, N Engl J Med, 364, pp. 806-817, (2011)
[3] Baglin T., The role of the laboratory in treatment with new oral anticoagulants, J Thromb Haemost, 11, pp. 122-128, (2013)
[4] Furie K.L., Goldstein L.B., Albers G.W., Et al., Oral antithrombotic agents for the prevention of stroke in nonvalvular atrial fibrillation: a science advisory for healthcare professionals from the American Heart Association/American Stroke Association, Stroke, 43, pp. 3442-3453, (2012)
[5] Urrutia G., Bonfill X., PRISMA declaration: a proposal to improve the publication of systematic reviews and meta-analyses, Med Clin (Barc)., 135, 11, pp. 507-511, (2010)
[6] Drummond M.F., Jefferson T.O., Guidelines for authors and peer reviewers of economic submissions to the BMJ, BMJ, 313, pp. 275-283, (1996)
[7] La Torre G., Nicolotti N., de Waure C., Ricciardi W., Development of a weighted scale to assess the quality of cost-effectiveness studies and an application to the economic evaluations of anti-HPV tetravalent vaccine, Italian J Public Health., 19, pp. 103-111, (2011)
[8] Gonzalez F.M., Veneziano M.A., Puggina A., Boccia S., Systematic review on the cost-effectiveness of genetic and electrocardiogram testing for long QT syndrome in infants and young adults, Value Health., 18, pp. 700-708, (2015)
[9] Giorgi M.A., Caroli C., Giglio N.D., Et al., Estimation of the cost-effectiveness of apixaban versus vitamin K antagonists in the management of atrial fibrillation in Argentina, Health Econ Rev., 5, 1, (2015)
[10] Janzic A., Kos M., Cost effectiveness of novel oral anticoagulants for stroke prevention in atrial fibrillation depending on the quality of warfarin anticoagulation control, Pharmacoeconomics., 33, 4, pp. 395-408, (2015)

← 1 2 3 4 5 →